Hives Study

Chronic spontaneous urticaria (CSU) is a condition that causes sufferers to break out in itchy hives that can last for 6 weeks or longer. Many people with this condition experience recurrent symptoms even when no external allergen or trigger is present, and many do not respond to antihistamine or other available treatments. Living with recurrent hives is uncomfortable and impacts the quality of life of those who have this condition and improved treatment options are needed.

CSU is caused by the inappropriate activation and degranulation of the skins mast cells. Momentum Clinical Research is conducting a study on an investigational treatment that is designed to reduce the activity and numbers of mast cells to treat people with CSU, reduce symptoms and improve quality of life.

The investigational treatment will be given via injection and the study will evaluate the effectiveness of different dosages to reduce symptoms.

During the first 24 weeks of the study, participants will be randomly assigned to be given the active study treatment every 4 or 8 weeks, or a placebo every 4 weeks. 

During the next 28 weeks, all participants will be assigned to receive the active study treatment every 4 or 8 weeks. 

Regular assessments will be conducted to monitor symptoms while on the investigational treatment.

Register your interest now to find out if you are eligible to participate and if this study is a good fit for you. 

By participating in a clinical trial, you’re helping shape the future of medicine. Your involvement not only benefits you but also contributes to developing groundbreaking treatments for others living with similar conditions. Together, we can improve healthcare for generations to come.